| __timestamp | GSK plc | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8246000000 | 504755000 |
| Thursday, January 1, 2015 | 9232000000 | 838526000 |
| Friday, January 1, 2016 | 9366000000 | 1177697000 |
| Sunday, January 1, 2017 | 9672000000 | 1320433000 |
| Monday, January 1, 2018 | 9915000000 | 1556200000 |
| Tuesday, January 1, 2019 | 11402000000 | 1834800000 |
| Wednesday, January 1, 2020 | 11456000000 | 1346000000 |
| Friday, January 1, 2021 | 10975000000 | 1824900000 |
| Saturday, January 1, 2022 | 8372000000 | 2115900000 |
| Sunday, January 1, 2023 | 9385000000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, operational efficiency is key. Over the past decade, Regeneron Pharmaceuticals, Inc. and GSK plc have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, GSK's SG&A expenses have consistently been higher, peaking at approximately $11.5 billion in 2020. In contrast, Regeneron has demonstrated a more conservative approach, with expenses growing from around $505 million in 2014 to $2.63 billion in 2023, marking a fivefold increase. This divergence highlights GSK's expansive operational scale compared to Regeneron's focused growth strategy. As the pharmaceutical landscape continues to shift, understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Dr. Reddy's Laboratories Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Evotec SE
Breaking Down SG&A Expenses: GSK plc vs ADMA Biologics, Inc.
GSK plc vs Amicus Therapeutics, Inc.: SG&A Expense Trends
GSK plc and Merus N.V.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: GSK plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights